Drug
Pozelimab clinical trials
Also written REGN3918.
- studies test it
- 16
- open now
- 6
- in phase 3
- 7
- first study started
- 2017
Keep track of what changes. Save the pozelimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 4
- Phase 3
- 7
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 1
Regeneron Pharmaceuticals (15) · Austin Neuromuscular Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses pozelimab is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyRecruitingPhase 3Regeneron PharmaceuticalsNCT06541704Written as Pozelimab
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksRecruitingPhase 3Regeneron PharmaceuticalsNCT05744921Written as Pozelimab
- Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult ParticipantsRecruitingPhase 1Regeneron PharmaceuticalsNCT07230834Written as Pozelimab
- A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyRecruitingPhase 3Regeneron PharmaceuticalsNCT07154745Written as Pozelimab
- A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) DiseaseRecruitingPhase 4Regeneron PharmaceuticalsNCT07142343Written as Pozelimab
- Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body MyositisRecruitingEarly Phase 1Austin Neuromuscular CenterNCT06479863Written as Pozelimab/Cemdisiran
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisActive, not recruitingPhase 3Regeneron PharmaceuticalsNCT05070858Written as Pozelimab + Cemdisiran
- Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)CompletedPhase 2/3Regeneron PharmaceuticalsNCT04209634Written as Pozelimab
- Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab TherapyCompletedPhase 2Regeneron PharmaceuticalsNCT04888507Written as Pozelimab
- Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab MonotherapyCompletedPhase 2Regeneron PharmaceuticalsNCT04811716Written as Pozelimab
- Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal HemoglobinuriaTerminatedPhase 3Regeneron PharmaceuticalsNCT05131204Written as Pozelimab
- Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedPhase 2Regeneron PharmaceuticalsNCT03946748Written as REGN3918
- REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.TerminatedPhase 3Regeneron PharmaceuticalsNCT04162470Written as REGN3918
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult VolunteersCompletedPhase 1Regeneron PharmaceuticalsNCT04601844Written as Pozelimab
- Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult ParticipantsCompletedPhase 1Regeneron PharmaceuticalsNCT04491838Written as Pozelimab
- Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy VolunteersCompletedPhase 1Regeneron PharmaceuticalsNCT03115996Written as REGN3918
Given in every arm · 2 — pozelimab is usual care beside what is tested
- A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentActive, not recruitingPhase 3Regeneron PharmaceuticalsNCT05133531Written as Pozelimab
- A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy VolunteersCompletedPhase 1Regeneron PharmaceuticalsNCT04940364Written as Pozelimab
Codes
What other systems call pozelimab · ClinicalTrials.gg INT002137
- MeSH (NLM) C000731768pozelimabOne source NLM
- UNII (FDA) 0JJ21K6L2IPOZELIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q121708361pozelimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166423PozelimabOne source FDA
- DrugBank DB15218One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731768 | pozelimab | One source NLM |
| UNII (FDA) | 0JJ21K6L2I | POZELIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q121708361 | pozelimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166423 | Pozelimab | One source FDA |
| DrugBank | DB15218 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.